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Abstract
The editorial comments on a recently published study in which 242 patients, with “stable” chronic kidney disease,
recruited during a hospital stay, were randomised either to receiving support from nephrologists (co-management
by primary care physicians and nephrologists), or to be managed by primary care physicians with written instructions
and nephrology consultations on demand. After a mean follow-up of 4 years, the results in terms of dialysis start,
hospitalisation and death were similar for both groups.
This study gave the possibility to discuss about the options of follow-up of CKD patients, including on one side the
advantage of a greater involvement of primary care physicians, who could oversee care by applying a common set of
simplified guidelines, and on the other one the importance of a direct and deep involvement of the specialists that
seems necessary in particular if personalised approaches have to be pursuit. The data of the present study are
somehow in disagreement with the literature, usually suggesting better outcomes in intensive treatment, in which
specialists are directly involved. The literature is heterogeneous, the goals vary and the populations are differently
selected. The compliance issue is probably one of the missing pieces of the puzzle, and specific interventions should
also be tailored to “reluctant” patients. Guidelines should probably be staring points for improvement, and not the
standard of care; the study herein discussed may suggest that primary care physicians may be of great help in granting
a good standard of care, hopefully as a baseline for further improvement, and personalised care.
Keywords: Chronic kidney disease, Chronic care, Compliance, Primary care physicians, Nephrology, Guidelines,
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Correspondence
In an elegant randomised controlled study, Saudan and
co-workers, at the prestigious University of Geneva, allo-
cated 242 patients, with “stable” chronic kidney disease,
recruited during a hospital stay, to one of two groups:
one whose follow-up included support from nephrologists
(co-management by primary care physicians and nephrol-
ogists); the other managed by primary care physicians with
written instructions on treatment goals, nephrology con-
sultations are on demand. After a mean follow-up of more
than 4 years, the results in terms of dialysis start, hospital-
isation and death were similar for both groups [1].
This result is interpreted by the authors as an indica-
tion that in the follow-up of CKD patients there should
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be greater involvement of primary care physicians, who
could oversee care by applying a common set of simplified
KDOQI guidelines, and that this policy would have a sig-
nificant positive effect on nephrologists’ workload [1].
Given the dire lack of studies on the management of
advanced CKD, the authors should be commended for
their ambitious, well-conducted long-term trial.
In the few other studies available, the results are heav-
ily dependent on setting and goals: in the study called
MASTERPLAN, an acronym for “Multifactorial Approach
and Superior Treatment Efficacy in Renal Patients with
the Aid of Nurse Practitioners”, the added intervention of
a nurse practitioner was associated with a striking 20% re-
duction in the composite negative endpoint, albeit not
with better cardiovascular outcomes (which is not surpris-
ing if we consider that cardiovascular care is probably a
more medical task, and that in most cases in advanced
CKD “les jeux –cardiovasculaires- sont faits”, and revers-
ing the biological clock is probably impossible with our
present treatment tools) [2]. A cluster randomised study
called ESCORT (Effectiveness of Integrated Care on
Delaying Progression of Stage 3–4 Chronic Kidney Dis-
ease in Rural Communities of Thailand), which involved
442 CKD patients, once more not surprisingly, demon-
strated that integrated care works better than follow-up by
only one specialist [3]. In this study the incidence of ad-
verse outcomes was about halved in patients followed with
the support of a large multidisciplinary team consisting of
two general practitioners, two chronic care nurses, a
pharmacist, a nutritionist, a physical therapist, a health
care officer, 3 to 5 village health care volunteers, and the
family members of CKD patients residing in the area [3].
Interestingly, the ESCORT study is in line with the
mother of all battles, the STENO2 study in diabetic pa-
tients, published in The New England Journal of Medi-
cine in 2003, which demonstrated, in 160 randomised
subjects, the clear superiority of intensive treatment,
which consisted in a series of interventions aimed at
behaviour modification and a stepwise introduction of
pharmacologic therapy overseen by a project team (doc-
tor, nurse, and dietician) at the Steno Diabetes Center [4].
This pivotal Danish study demonstrated a significant ad-
vantage for all the tested outcomes in diabetic patients, in-
cluding two of particular relevance for the nephrology
community, i.e. the development of kidney disease and the
need for renal replacement therapy [4, 5].
Unlike previous positive results, and in line with a
completely different selection of its study population,
was a Canadian study aimed at assessing the possible ad-
vantages of a nurse-coordinated model of care. The pa-
tients enrolled were identified from laboratory records
as having a low e-GFR level, but for the most part (96%)
had not previously been followed up by a specialist and
the study found that this approach did not improve
outcomes and resulted in a higher pill burden [6]. The
authors conclude that some CKD patients, like those
identified through community laboratories, do not have
progressive kidney disease and, in such a context, spe-
cialized nephrology care cannot make a difference [6].
A similar trial was conducted in the United States with
a different selection of patients with stages 4–5 CKD,
who were already receiving nephrology care in various
settings, and demonstrated an advantage in reducing
hospitalisation rates and improving patients’ preparation
for renal replacement therapy in the arm with coordi-
nated care [7].
Three recent systematic reviews have also addressed
this question. While the first two conclude that data in-
dicate that the involvement of different professionals
(nurses, primary care phsydsicians and others) has a
positive effect, the third one, while acknowledging the
advantages that have been reported, points out the het-
erogeneity of the studies published in terms of multidis-
ciplinary CKD clinic composition, entry criteria, follow-
up, and type of care [8–10].
Given this background, how should we read the nega-
tive results of the Swiss study?
A simplistic conclusion is that it is not worth offering
nephrology care (and consequently even less important
to offer complex integrated care) to patients with ad-
vanced CKD, since, with brief, clear, written instructions
summarizing the current CKD guidelines, knowledgeable
general practitioners perform as well as nephrology spe-
cialists, at least for patients who have a “stable” CKD.
The paper may therefore seem to be in agreement with
those who consider that the guidelines spell the end of
specialist care in treatment of this illness [11].
On a second glance, however, our reading of the re-
sults could differ significantly.
The paper design is unique, with respect to the other
studies cited, in which intervention involves an “add-on”
to standard care. The Swiss study’s proposal should in-
stead be seen as a “subtract-from” approach, as the usual
nephrology care is absent from one of the two arms [1].
The difference reflects something deeper, philosophic-
ally as well as clinically: an add-on approach is chosen
when we try to answer the question of what we can do
to improve care that we perceive as insufficient, and un-
satisfactory. In this regard, it is logical that each study
envisions different additions: there are no village health
volunteers in North American cities, nor is it likely that
there will be specialised managing nurses in remote
Thailand villages. Each study adds what is considered to
be of added value, within a widespread policy of sustain-
ability. Given the heterogeneity described above, the
common objective, expressed in the different back-
grounds of the studies, is finding what can be done to
integrate services to improve outcomes.
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Conversely, the original study commented on, in
which the interventional arm offers “less care” than usu-
ally given, implicitly considers that patients (i.e. most pa-
tients, stable patients, "non-progressive patients …) are
already receiving the best care presently available, and
that this care is faithfully reflected in the current guide-
lines [1].
This position is interesting, and outside the box.
At present healthcare systems are increasingly focus-
sing on how to improve care of advanced CKD, France,
for example, has established a bundle reimbursement
system, which requires that nephrology care be inte-
grated with educational programs and nutritional man-
agement. Given this trend, suggesting that there are
cases who can safely receive “lighter” care may contrib-
ute to clarifying ideas.
The selection of patients is an important issue; inter-
estingly, in the Swiss study, patients with previously
known CKD did less well than those who had not re-
ceived follow-up care. This can be seen as an indication
of how well the Swiss system functions, since the logical
interpretation is that the patients with poorer prognoses
had been already identified and referred. More interest-
ingly, however, of those that theoretically could have
been randomised, the patients who declined had worse
outcomes. This “self-selection” by patients is probably
one of the reasons why the ones who accepted being
randomised did better, and it is reasonable to suppose
that in the refusal cohort non-adherence was a major
negative factor. In this regard, one of the advantages of
the trial was to identify a population in which lack of
participation was probably the epiphenomenon of a
more generalized negative attitude towards care. This is
a population that should be systematically identified, and
should be encouraged to seek treatment via tailored in-
terventions (education, follow-up reminders, empower-
ment programs).
In the description of a standard intervention it is not
fully clear what “dietician and lifestyle counselling”
means, and who provides this in the context of a 30-min
consultation. Notably, in no part of the paper, is “standard
care” described as involving a team and consisting in coor-
dinated personalised care. While the authors cite as a
limitation failure to prescribe low−/very low-protein sup-
plemented diets (very low supplemented diets usually feas-
ible in 10–20% of patients) or strict sodium restriction
(rarely recommended in advanced CKD), they leave us
with the idea that patients are managed in accordance
with the international nutritional guidelines that, at the
time of publication of this paper, are twenty years old [11].
As it is, this important paper may convey the message
that a good nephrologist is no better than an educated
primary care physician at following the KDOQI guide-
lines. It stresses that, given similar clinical conditions
(fulfilling the same enrolment criteria), non-clinical
factors (e.g. willingness to participate) make a major
difference in patient survival, and indirectly suggests that
interventions should also be tailored to “reluctant”
patients.
Actually, there is an important missing point: the sys-
tem of care included treatment advice for the general
practitioners, provided by nephrologists on request. De-
tails of the requests, their type and frequency are not
provided in the paper, but it is reasonable to think that
this distant “maternage” was crucial in the attainment of
the results. Indeed, as the recent pandemic has sown,
there is a great potential for implementing remote care,
for improving, hopefully without replacing, standard
one. This could help better coping with the limited
number of specialists in many highly resourced coun-
tries, as well as the limited number of physicians in
resource-limited settings; how to maintain a distant but
humane approach to our chronic patients will probably
represent our next challenge.
Some nephrologists strongly believe, and I am one of
them, that guidelines should be staring points for im-
provement, and not the standard of care. Guidelines
change, and are often already outdated when they first
appear [12]. Large, influential, settings, particularly
university-affiliated hospitals, should be examples of new
approaches to treatment and better care; personalization
of treatment, integrated care, and dietary management
offer new opportunities and are continuously being up-
dated. The lack of difference in the effect of guideline-
driven care, observed in compliant patients with stable
CKD in this study, can be read as a good reason to go
beyond the guidelines to improve the care of patients
with advanced CKD.
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